Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
Event:
ESC Congress 2023
Topic:
Pharmacotherapy
Session:
Diabetes and the heart